Nexus Pharmaceuticals Announces Launch of Potassium Chloride in Water for Injection

Nexus Pharmaceuticals Announces Launch of Potassium Chloride in Water for Injection




Nexus Pharmaceuticals Announces Launch of Potassium Chloride in Water for Injection

LINCOLNSHIRE, Ill.–(BUSINESS WIRE)–#ANDA–Nexus Pharmaceuticals announced the launch of Potassium Chloride in Water for Injection in 10mEq/100mL, 10mEq/50mL, and 20mEq/50mL Single-Dose IV bags.


“Nexus is proud to introduce Potassium Chloride IV Bags to our suite of products,” said Usman Ahmed, Chief Operating Officer of Nexus Pharmaceuticals. “As a critical product for patients, Potassium Chloride is consistently on shortage. We are proud to be a part of the solution to the drug shortage problem by removing obstacles for patient care.”

Nexus Pharmaceuticals’ Potassium Chloride in Water for Injection will be available in environmentally friendly cartons of 24 IV bags.

About Potassium Chloride in Water for Injection

Potassium Chloride in Water for Injection is a sterile, nonpyrogenic, highly concentrated, ready-to-use solution of Potassium Chloride, USP in Water for Injection, USP for electrolyte replenishment in a single-dose container for intravenous administration. Potassium Chloride Injection is indicated in the treatment of potassium deficiency states when oral replacement is not feasible.

For prescribing information, please see the following link.

About Nexus Pharmaceuticals, Inc.

Nexus Pharmaceuticals, Inc., a US-based healthcare company and certified diverse supplier specializes in innovative processes to make difficult-to-manufacture specialty and generic drugs that are easier to use, less labor-intensive, and more streamlined in practice. Nexus ensures that its high-quality FDA-approved drugs fulfill a critical unmet medical need and delivers dependable life-saving treatment options when and where they’re needed most. For more information about Nexus Pharmaceuticals, including our new state-of-the-art Wisconsin manufacturing facility, please visit https://www.nexuspharma.net/project-tomorrow/.

Contacts

Deana Mndrucic

dmndrucic@nexuspharma.net
847-996-3790